GlassScriptPhysician profile
Sandra M Kurpela
NPI 1215198569
$4,876.23
in general payments reported to CMS, 2019-2025
22 companies · $626 in 2025
The $626 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $632 · 2022: $1,006 · 2023: $1,854 · 2024: $758 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,671 · Travel and Lodging: $472 · Education: $95.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,671.00 |
| Travel and Lodging | $471.82 |
| Education | $95.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $712.91 | 2022-2023 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $553.58 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.60 | 2021-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $413.94 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $344.86 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $306.31 | 2023-2024 | Farxiga, Brilinta |
| Amgen INC. | $210.59 | 2022-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $208.10 | 2022-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $176.52 | 2023-2025 | Verquvo, Winrevair |
| Novo Nordisk INC | $171.44 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $125.00 | 2025 | Amvuttra |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2022 | |
| Bridgebio Pharma, INC. | $124.46 | 2025 | Attruby |
| Madrigal Pharmaceuticals | $121.49 | 2025 | Rezdiffra |
| Teva Pharmaceuticals USA, INC. | $114.30 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $112.36 | 2021 | |
| Pfizer INC. | $103.73 | 2025 | |
| Abbvie INC. | $95.25 | 2021 | |
| Inari Medical, INC. | $94.48 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $94.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.82 | 2021-2025 | |
| Getinge USA Sales, LLC | $57.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Kurpela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.